Gsa Capital Partners LLP Aclaris Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 255,032 shares of ACRS stock, worth $737,042. This represents 0.02% of its overall portfolio holdings.
Number of Shares
255,032
Previous 336,677
24.25%
Holding current value
$737,042
Previous $370,000
20.81%
% of portfolio
0.02%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding ACRS
# of Institutions
84Shares Held
50.7MCall Options Held
30.6KPut Options Held
1K-
Bml Capital Management, LLC Zionsville, IN14.3MShares$41.2 Million9.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$13.5 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.37MShares$9.74 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.01MShares$8.69 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.75MShares$7.96 Million0.11% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $193M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...